Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Rosales, Carlos; Rosales, Ricardo

doi:10.5772/intechopen.69548

Cited by 4 publications

(6 citation statements)

References 119 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The cellular immune response plays an important role in eliminating HPV-infected cells. Activation of CTL plays an important role in the recognition of HPV antigens, especially E1 and E2, which are expressed at several stages of viral infection . In addition, CD4+ (HTL) activated by APCs differentiates into Th1, Th2, or Treg cells according to the cytokines produced.…”

Section: Resultsmentioning

confidence: 99%

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Rizarullah,

Aditama,

Giri-Rachman

et al. 2024

ACS Omega

View full text Add to dashboard Cite

One of the deadliest malignant cancer in women globally is cervical cancer. Specifically, cervical cancer is the second most common type of cancer in Indonesia. The main infectious agent of cervical cancer is the human papilloma virus (HPV). Although licensed prophylactic vaccines are available, cervical cancer cases are on the rise. Therapy using multiepitope-based vaccines is a very promising therapy for cervical cancer. This study aimed to develop a multiepitope vaccine based on the E1 and E2 proteins of HPV 16, 18, 45, and 52 using in silico. In this study, we develop a novel multiepitope vaccine candidate using an immunoinformatic approach. We predicted the epitopes of the cytotoxic T lymphocyte (CTL) and helper T lymphocyte (HTL) and evaluated their immunogenic properties. Population coverage analysis of qualified epitopes was conducted to determine the successful use of the vaccine worldwide. The epitopes were constructed into a multiepitope vaccine by using AAY linkers between the CTL epitopes and GPGPG linkers between the HTL epitopes. The tertiary structure of the multiepitope vaccine was modeled with AlphaFold and was evaluated by Prosa-web. The results of vaccine construction were analyzed for B-cell epitope prediction, molecular docking with Toll like receptor-4 (TLR4), and molecular dynamics simulation. The results of epitope prediction obtained 4 CTL epitopes and 7 HTL epitopes that are eligible for construction of multiepitope vaccines. Prediction of the physicochemical properties of multiepitope vaccines obtained good results for recombinant protein production. The interaction showed that the interaction of the multiepitope vaccine-TLR4 complex is stable based on the binding free energy value −106.5 kcal/mol. The results of the immune response simulation show that multiepitope vaccine candidates could activate the adaptive and humoral immune systems and generate long-term B-cell memory. According to these results, the development of a multiepitope vaccine with a reverse vaccinology approach is a breakthrough to develop potential cervical cancer therapeutic vaccines.

show abstract

Section: Resultsmentioning

confidence: 99%

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Rizarullah,

Aditama,

Giri-Rachman

et al. 2024

ACS Omega

View full text Add to dashboard Cite

show abstract

“…Prophylactic vaccines aim to prevent infection by a pathogen, and thus protect the individual from future contact through immunological memory [29]. The application of prophylactic vaccines induces an adaptive immune response primarily focused on the humoral immune response [30].…”

Section: Therapeutic Vaccines For Hpv-associated Malignanciesmentioning

confidence: 99%

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

et al. 2022

View full text Add to dashboard Cite

Prophylactic vaccines against human papillomavirus (HPV) have proven efficacy in those who have not been infected by the virus. However, they do not benefit patients with established tumors. Therefore, the development of therapeutic options for HPV-related malignancies is critical. Third-generation vaccines based on nucleic acids are fast and simple approaches to eliciting adaptive immune responses. However, techniques to boost immunogenicity, reduce degradation, and facilitate their capture by immune cells are frequently required. One option to overcome this constraint is to employ delivery systems that allow selective antigen absorption and help modulate the immune response. This review aimed to discuss the influence of these different systems on the response generated by nucleic acid vaccines. The results indicate that delivery systems based on lipids, polymers, and microorganisms such as yeasts can be used to ensure the stability and transport of nucleic acid vaccines to their respective protein synthesis compartments. Thus, in view of the limitations of nucleic acid-based vaccines, it is important to consider the type of delivery system to be used—due to its impact on the immune response and desired final effect.

show abstract

“…The difference of the Giant condyloma acuminatum is that it is more proliferating and penetrates deeper tissues than squamous cell tumors, respects the basement membrane and does not metastasize. The rest of the pathologies raised is discarded by serology and other complementary [8,11,12].…”

Section: Histological Studymentioning

confidence: 99%

“…Some cases may even require abdominoperineal amputation. Other treatments that have been used in some cases are chemo and radiotherapy, as well as topical treatments although the available bibliographic evidence is not conclusive regarding the systematic use of them, tending in general terms to be ineffective [12][13][14]. malignant cells and nucleoli prominent rosés with inclusion bodies in the epidermis (Figures 7-10).…”

Section: Histological Studymentioning

confidence: 99%

Giant Cumulated Condyloma (Tumor of Buschke-Lõwenstein)- A Case Report

Jfr¹,

Jas²,

Ocl³

et al. 2019

J Surg Open Access

View full text Add to dashboard Cite

The condylomata acuminatum or genital warts are produced by the human papillomavirus. Infection typically occurs when host, basal cells are exposed to viral infection through a damaged epithelial barrier, such as during sexual intercourse or as a product of other minor skin abrasions. In a few occasions, they can evolve with a marked growth and cause the well-known Buschke-Löwenstein syndrome or Giant condyloma acuminatum. We present a patient with Giant condylomata acuminata in the inguinal and anal regions that were surgically treated with exeresis of the inguinal lesions and electro fulguration of the annals with satisfactory evolution, without tumor recurrence at three months.

show abstract

Prophylactic and Therapeutic Vaccines against Human Papillomavirus Infections

Cited by 4 publications

References 119 publications

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Designing a Novel Multiepitope Vaccine from the Human Papilloma Virus E1 and E2 Proteins for Indonesia with Immunoinformatics and Molecular Dynamics Approaches

Enhancing the Effect of Nucleic Acid Vaccines in the Treatment of HPV-Related Cancers: An Overview of Delivery Systems

Giant Cumulated Condyloma (Tumor of Buschke-Lõwenstein)- A Case Report

Contact Info

Product

Resources

About